Alaunos Therapeutics

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 – October 1, 2022.

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Danielle Dudgeon - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research and Development Abhishek Srivastava - Vice President of Technical Operations Mike Wong - Vice President of Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald Thomas Flaten - Lake Street Capital Markets Yale Jen - Laidlaw & Company Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by.

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q2 2022 Results - Earnings Call Transcript

HOUSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the second quarter ended June 30, 2022.

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion.

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Graybug Vision

HTG Molecular Diagnostics

Smart for Life Inc

Vallon Pharmaceuticals

Penny stocks to watch right now. The post Best Penny Stocks For July 2022?

Best Penny Stocks For July 2022? 5 To Watch Right Now

Benitec Biopharma Limited Sponsored ADR

Clovis Oncology

Invitae

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

Imperial Petroleum

OneConnect Financial Tech Co Ltd ADR

Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out in Mid-June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out in Mid-June 2022

HOUSTON--(BUSINESS WIRE)-- #antibodies--CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the formation of a scientific advisory board. The board will advise the company opportunities to apply its TIMING™ platform across a variety of therapeutic areas to improve patient care. Initial members of the scientific advisory board include Rebecca Berdeaux, PhD, Dimitrios Kontoyiannis, MD, PhD, and Laurence Cooper, MD, PhD. Rebecc

CellChorus Announces Scientific Advisory Board

HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL June 3-7, 2022.

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alex Lobo - Stern, Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Nick Abbott - Wells Fargo Prakhar Agrawal - Cantor Fitzgerald Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to Alaunos Therapeutics First Quarter 2022 Financial Results Conference Call.

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript

Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development at Alaunos Therapeutics will present at the upcoming H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami Beach, FL.

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

Mountain Crest Acquisition Corp II

Mind Medicine MindMed

Sunworks

Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks With Huge Potential According To 4 Wall Street Analysts

Ziopharm (TCRT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Ziopharm (TCRT) a New Buy Stock

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the Company's membrane-bound interleukin-15 (mbIL-15) program as a potentially potent cell therapy targeting hotspot mutations expressed in solid tumors at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C. and virtually May 16-19, 2022.

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that the first patient has been dosed in its TCR-T Library Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications using the Company's Sleeping Beauty transposon/transposase technology.

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Aterian

Athersys

Creative Medical Technology Holdings

Clever Leaves Holdings Inc

CYREN

Enservco

ION Geophysical

Short squeeze penny stocks to watch. The post Penny Stocks To Buy?

Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now

Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the fourth quarter and full year ended December 31, 2021.

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company's Chief Executive Officer, Kevin S. Boyle Sr., and Vice President of Research & Development, Drew Deniger, are scheduled to participate in the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 9:20am ET.

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

News for Alaunos Therapeutics Stock (TCRT)